Arbutus Biopharma (ABUS) EBT Margin (2009 - 2026)

Arbutus Biopharma recorded quarterly EBT Margin of 94.74% in Q1 2026, up 122.47% quarter-over-quarter from 421.6% in Q4 2025, and up 148533.0% year-over-year from N/an in Q1 2025.

Arbutus Biopharma's EBT Margin history runs 18 years deep, the most recent figure standing at 94.74% for Q1 2026.

  • In Q1 2026, EBT Margin rose 148533.0% year-over-year to 94.74%; the TTM figure through Mar 2026 stood at 83.6% (up 127896.0% YoY), while the FY2025 annual figure was 242.77%, up 89027.0% from the prior year.
  • EBT Margin came in at 94.74% for Q1 2026 at Arbutus Biopharma, up from 421.6% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 94.74% in Q1 2026 to a low of 1472.89% in Q3 2024.
  • A 5-year average of 618.5% and a median of 421.6% in 2025 frame the typical range for EBT Margin.
  • Across the five-year window, EBT Margin tumbled 104129 bps in 2024 and soared 148533 bps in 2026, its largest moves.
  • Arbutus Biopharma's EBT Margin stood at 351.19% in 2022, then slumped by 156 bps to 900.33% in 2023, then rose by 12 bps to 794.09% in 2024, then surged by 47 bps to 421.6% in 2025, then jumped by 122 bps to 94.74% in 2026.
  • According to Business Quant data, EBT Margin over the past three periods registered 94.74%, 421.6%, and 1461.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 41.95%
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 18.99%
10 Arbutus Biopharma 883.58 Mn 883.58 Mn - 94.74%

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 94.74%
Dec 31, 2025 -421.60%
Sep 30, 2025 -1,461.25%
Jun 30, 2025 23.30%
Mar 31, 2025 -1,390.59%
Dec 31, 2024 -794.09%
Sep 30, 2024 -1,472.89%
Jun 30, 2024 -1,146.47%
Mar 31, 2024 -1,165.93%
Dec 31, 2023 -900.33%
Sep 30, 2023 -431.60%
Jun 30, 2023 -367.53%
Mar 31, 2023 -244.34%
Dec 31, 2022 -351.19%
Sep 30, 2022 -295.14%
Jun 30, 2022 -99.66%
Mar 31, 2022 -89.98%
Dec 31, 2021 -665.03%
Sep 30, 2021 -573.59%
Jun 30, 2021 -832.42%
Mar 31, 2021 -775.25%
Dec 31, 2020 -714.25%
Sep 30, 2020 -1,231.45%
Jun 30, 2020 -930.45%
Mar 31, 2020 -929.64%
Dec 31, 2019 -1,523.73%
Sep 30, 2019 -3,108.76%
Jun 30, 2019 -3,570.44%
Mar 31, 2019 -3,424.30%
Dec 31, 2018 -1,087.54%
Sep 30, 2018 -1,811.91%
Jun 30, 2018 248.47%
Mar 31, 2018 -1,236.14%
Dec 31, 2017 -2,377.70%
Sep 30, 2017 -168.31%
Jun 30, 2017 -1,756.98%
Mar 31, 2017 -7,648.09%
Dec 31, 2016 -132,734.87%
Sep 30, 2016 -2,531.65%
Jun 30, 2016 -63,062.78%
Mar 31, 2016 -3,272.47%
Dec 31, 2015 -61.88%
Sep 30, 2015 -1,086.79%
Jun 30, 2015 -432.73%
Mar 31, 2015 -380.26%
Dec 31, 2014 -243.72%
Sep 30, 2014 -149.93%
Jun 30, 2014 -506.13%
Mar 31, 2014 -131.17%
Dec 31, 2013 -307.71%
Sep 30, 2013 -117.88%
Jun 30, 2013 -103.59%
Mar 31, 2013 -136.68%
Dec 31, 2012 -150.65%
Sep 30, 2012 -57.34%
Jun 30, 2012 -70.53%
Mar 31, 2012 -72.52%
Dec 31, 2011 -55.81%
Sep 30, 2011 -39.63%
Jun 30, 2011 -81.68%
Mar 31, 2011 -70.77%
Dec 31, 2010 -30.07%
Sep 30, 2010 -62.16%
Jun 30, 2010 -169.01%
Mar 31, 2010 -168.09%
Dec 31, 2009 -31.63%
Sep 30, 2009 -77.85%